e-learning
resources
ERJ
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis
Gautier-Veyret Elodie, Arnaud Claire, Bäck Magnus, Pépin Jean-Louis, Petri Marcelo H., Baguet Jean-Philippe, Tamisier Renaud, Lévy Patrick, Stanke-Labesque Françoise
Source:
Eur Respir J 2013; 42: 404-413
Journal Issue:
August
Disease area:
Sleep and breathing disorders
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Gautier-Veyret Elodie, Arnaud Claire, Bäck Magnus, Pépin Jean-Louis, Petri Marcelo H., Baguet Jean-Philippe, Tamisier Renaud, Lévy Patrick, Stanke-Labesque Françoise. Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis. Eur Respir J 2013; 42: 404-413
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA)
The search for realistic evidence on the outcomes of obstructive sleep apnoea
PERIPHERAL ARTERIAL TONOMETRY AND INTIMA MEDIA THICKNESS IN OBSTRUCTIVE SLEEP APNEA.
Related content which might interest you:
Role of RhoA/Rho-kinase pathway in the regulation of eNOS activity in COPD patients
Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Year: 2010
Attenuated expression and activity of dimethylarginine dimethylaminohydrolase may play a key role in monocrotaline-induced pulmonary hypertension by accumulation of endogenous NOS inhibitors in rats
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension
Source: Eur Respir J, 54 (6) 1900378; 10.1183/13993003.00378-2019
Year: 2019
Oral presentation: Genetic or pharmacologic inhibition of ATX stimulates LPS-induced pulmonary inflammation
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Effect of cyclooxygenase-2 inhibition on lung inflammation and hypoxia-inducible factor-1 signalling in COPD model
Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia
Year: 2017
6-aminonicotinamide ameliorates pulmonary fibrosis by suppressing the TGF-beta1 activated Smad signalling pathway
Source: Virtual Congress 2020 – Translational therapeutic advances
Year: 2020
Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension
Source: Eur Respir J 2016; 48: 470-483
Year: 2016
Oral presentation: Protease-activated receptor-2 plays a pivotal role in pulmonary fibrosis by inducing myofibroblast differentiation and tissue factor up-regulation
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010
Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Dual inhibition of thromboxane synthase and 5-lipoxygenase, potentially significant mechanism for the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 264s
Year: 2001
Modulation of oxidative stress pathway by arginase inhibition: Evaluation in an animal model of chronic pulmonary inflammation
Source: Annual Congress 2010 - Regulation of airway pharmacology
Year: 2010
TSC1/mTOR pathway promotes hypoxia-induced pulmonary hypertension in mice
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Effect of endothelin on DNA synthesis in human bronchial eipthelial cells: role of MAPK cascade
Source: Eur Respir J 2001; 18: Suppl. 33, 476s
Year: 2001
Intermittent hypoxia activates the Interleukin (IL)-1ß and nuclear factor (NF)?B signaling pathway in primary murine macrophages
Source: International Congress 2019 – Insights into the pathophysiology of sleep-disordered breathing
Year: 2019
A novel piperidine attenuates pulmonary arterial hypertension via regulating BMP2 and PTGS2 levels
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Endothelin-1 contributes to the downregulation of BMP/BMPR2 signaling induced by hypoxia
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept